IGM Biosciences Announces Third Quarter 2024 Financial Results …
6 days ago · In This Article: IGMS. – Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 –. – IGM-2644 ...
News - IGM Biosciences
Aug 14, 2024 · News. MOUNTAIN VIEW, Calif. , Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming investor conferences: Guggenheim Healthcare. – …
Home - IGM Biosciences
6 days ago · Make an impact at IGM. Help us bring a new class of antibody medicines to patients. » LEARN MORE ABOUT BEING PART OF THE IGM TEAM. Recent News. November 8, 2024. IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update. November 4, 2024.
IGM Biosciences' New Found Focus: Pivots From Cancer To …
Oct 1, 2024 · On Tuesday, IGM Biosciences Inc. (NASDAQ:IGMS) announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in developing T cell-engaging IgM antibodies for...
IGM Biosciences Announces Strategic Pivot to Focus Exclusively …
Sep 30, 2024 · IGMS. – Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus...
IGM Biosciences Announces Third Quarter 2024 Financial Results …
Sep 30, 2024 · IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases. IGM’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only 2 ...
IGM Biosciences Announces Third Quarter 2024 Financial Results …
6 days ago · About IGM Biosciences, Inc. IGM Biosciences is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and ...
IGM Biosciences Announces Strategic Pivot to Focus Exclusively …
Sep 30, 2024 · IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity. – Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus –.
Top 1% Biotech, IGM Biosciences, Plummets On Scrapped Drug, …
Oct 1, 2024 · IGM stock crashed Tuesday after the biotech company scrapped development of a cancer drug and announced three of its executives — including former CEO Fred Schwarzer — have stepped down. The...
Sanofi shrinks $6B biobucks deal with IGM - Fierce Biotech
Apr 17, 2024 · Sanofi is shrinking a collaboration with IGM Biosciences by half, shedding three cancer targets to focus on three immunology and inflammation targets.
- Some results have been removed